<?xml version="1.0" encoding="UTF-8"?>
<protein>
  <version>3.5</version>
  <creation_date>2013-01-15 19:06:07 -0700</creation_date>
  <update_date>2013-05-27 11:35:00 -0600</update_date>
  <accession>HMDBP02547</accession>
  <secondary_accessions>
    <accession>8046</accession>
    <accession>HMDBP04310</accession>
  </secondary_accessions>
  <protein_type>Unknown</protein_type>
  <synonyms>
    <synonym>DA transporter</synonym>
    <synonym>DAT</synonym>
    <synonym>Solute carrier family 6 member 3</synonym>
  </synonyms>
  <gene_name>SLC6A3</gene_name>
  <general_function>Involved in neurotransmitter:sodium symporter activity</general_function>
  <specific_function>Amine transporter. Terminates the action of dopamine by its high affinity sodium-dependent reuptake into presynaptic terminals.
</specific_function>
  <pathways>
    <pathway>
      <name>Dopaminergic synapse</name>
      <smpdb_id/>
      <kegg_map_id>map04728</kegg_map_id>
    </pathway>
    <pathway>
      <name>Parkinson's disease</name>
      <smpdb_id/>
      <kegg_map_id>map05012</kegg_map_id>
    </pathway>
    <pathway>
      <name>Cocaine addiction</name>
      <smpdb_id/>
      <kegg_map_id>map05030</kegg_map_id>
    </pathway>
    <pathway>
      <name>Amphetamine addiction</name>
      <smpdb_id/>
      <kegg_map_id>map05031</kegg_map_id>
    </pathway>
    <pathway>
      <name>Alcoholism</name>
      <smpdb_id/>
      <kegg_map_id>map05034</kegg_map_id>
    </pathway>
  </pathways>
  <metabolite_associations>
    <metabolite>
      <accession>HMDB00588</accession>
      <name>Sodium</name>
    </metabolite>
    <metabolite>
      <accession>HMDB01510</accession>
      <name>Bupropion</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00073</accession>
      <name>Dopamine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14328</accession>
      <name>Amphetamine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14337</accession>
      <name>Phentermine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14390</accession>
      <name>Benzatropine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14566</accession>
      <name>Methylphenidate</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14619</accession>
      <name>Duloxetine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14718</accession>
      <name>Mazindol</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14859</accession>
      <name>Procaine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14864</accession>
      <name>Trimipramine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14883</accession>
      <name>Modafinil</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14968</accession>
      <name>Phenmetrazine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15003</accession>
      <name>Benzphetamine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15043</accession>
      <name>Cocaine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15072</accession>
      <name>Diethylpropion</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15237</accession>
      <name>Sibutramine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15277</accession>
      <name>Diphenylpyraline</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15280</accession>
      <name>Nefazodone</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15292</accession>
      <name>Chloroprocaine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15385</accession>
      <name>Lisdexamfetamine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15508</accession>
      <name>Fencamfamine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15516</accession>
      <name>Dextroamphetamine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15517</accession>
      <name>Methamphetamine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15647</accession>
      <name>Dexmethylphenidate</name>
    </metabolite>
  </metabolite_associations>
  <go_classifications>
    <go_class>
      <category>function</category>
      <description>dopamine:sodium symporter activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>transporter activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>transmembrane transporter activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>neurotransmitter transporter activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>neurotransmitter:sodium symporter activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>establishment of localization</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>transport</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>neurotransmitter transport</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>component</category>
      <description>membrane</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>component</category>
      <description>cell part</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>component</category>
      <description>membrane part</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>component</category>
      <description>intrinsic to membrane</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>component</category>
      <description>integral to membrane</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>component</category>
      <description>integral to plasma membrane</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>Cellular component</category>
      <description>axon</description>
      <go_id>GO:0030424</go_id>
    </go_class>
    <go_class>
      <category>Cellular component</category>
      <description>cytoplasm</description>
      <go_id>GO:0005737</go_id>
    </go_class>
    <go_class>
      <category>Cellular component</category>
      <description>integral to membrane</description>
      <go_id>GO:0016021</go_id>
    </go_class>
    <go_class>
      <category>Cellular component</category>
      <description>integral to plasma membrane</description>
      <go_id>GO:0005887</go_id>
    </go_class>
    <go_class>
      <category>Cellular component</category>
      <description>neuronal cell body</description>
      <go_id>GO:0043025</go_id>
    </go_class>
    <go_class>
      <category>Cellular component</category>
      <description>plasma membrane</description>
      <go_id>GO:0005886</go_id>
    </go_class>
    <go_class>
      <category>Molecular function</category>
      <description>dopamine binding</description>
      <go_id>GO:0035240</go_id>
    </go_class>
    <go_class>
      <category>Molecular function</category>
      <description>dopamine transmembrane transporter activity</description>
      <go_id>GO:0005329</go_id>
    </go_class>
    <go_class>
      <category>Molecular function</category>
      <description>dopamine:sodium symporter activity</description>
      <go_id>GO:0005330</go_id>
    </go_class>
    <go_class>
      <category>Molecular function</category>
      <description>drug binding</description>
      <go_id>GO:0008144</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>adenohypophysis development</description>
      <go_id>GO:0021984</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>aging</description>
      <go_id>GO:0007568</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>cell death</description>
      <go_id>GO:0008219</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>dopamine biosynthetic process</description>
      <go_id>GO:0042416</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>dopamine catabolic process</description>
      <go_id>GO:0042420</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>dopamine transport</description>
      <go_id>GO:0015872</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>lactation</description>
      <go_id>GO:0007595</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>locomotory behavior</description>
      <go_id>GO:0007626</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>neurotransmitter biosynthetic process</description>
      <go_id>GO:0042136</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>positive regulation of multicellular organism growth</description>
      <go_id>GO:0040018</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>prepulse inhibition</description>
      <go_id>GO:0060134</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>regulation of dopamine metabolic process</description>
      <go_id>GO:0042053</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>response to cAMP</description>
      <go_id>GO:0051591</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>response to cocaine</description>
      <go_id>GO:0042220</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>response to drug</description>
      <go_id>GO:0042493</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>response to ethanol</description>
      <go_id>GO:0045471</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>response to iron ion</description>
      <go_id>GO:0010039</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>response to nicotine</description>
      <go_id>GO:0035094</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>sensory perception of smell</description>
      <go_id>GO:0007608</go_id>
    </go_class>
  </go_classifications>
  <subcellular_locations>
    <subcellular_location>Membrane</subcellular_location>
    <subcellular_location>Multi-pass membrane protein</subcellular_location>
  </subcellular_locations>
  <gene_properties>
    <chromosome_location>5</chromosome_location>
    <locus>5p15.3</locus>
    <gene_sequence>&gt;1863 bp
ATGAGTAAGAGCAAATGCTCCGTGGGACTCATGTCTTCCGTGGTGGCCCCGGCTAAGGAG
CCCAATGCCGTGGGCCCGAAGGAGGTGGAGCTCATCCTTGTCAAGGAGCAGAACGGAGTG
CAGCTCACCAGCTCCACCCTCACCAACCCGCGGCAGAGCCCCGTGGAGGCCCAGGATCGG
GAGACCTGGGGCAAGAAGATCGACTTTCTCCTGTCCGTCATTGGCTTTGCTGTGGACCTG
GCCAACGTCTGGCGGTTCCCCTACCTGTGCTACAAAAATGGTGGCGGTGCCTTCCTGGTC
CCCTACCTGCTCTTCATGGTCATTGCTGGGATGCCACTTTTCTACATGGAGCTGGCCCTC
GGCCAGTTCAACAGGGAAGGGGCCGCTGGTGTCTGGAAGATCTGCCCCATACTGAAAGGT
GTGGGCTTCACGGTCATCCTCATCTCACTGTATGTCGGCTTCTTCTACAACGTCATCATC
GCCTGGGCGCTGCACTATCTCTTCTCCTCCTTCACCACGGAGCTCCCCTGGATCCACTGC
AACAACTCCTGGAACAGCCCCAACTGCTCGGATGCCCATCCTGGTGACTCCAGTGGAGAC
AGCTCGGGCCTCAACGACACTTTTGGGACCACACCTGCTGCCGAGTACTTTGAACGTGGC
GTGCTGCACCTCCACCAGAGCCATGGCATCGACGACCTGGGGCCTCCGCGGTGGCAGCTC
ACAGCCTGCCTGGTGCTGGTCATCGTGCTGCTCTACTTCAGCCTCTGGAAGGGCGTGAAG
ACCTCAGGGAAGGTGGTATGGATCACAGCCACCATGCCATACGTGGTCCTCACTGCCCTG
CTCCTGCGTGGGGTCACCCTCCCTGGAGCCATAGACGGCATCAGAGCATACCTGAGCGTT
GACTTCTACCGGCTCTGCGAGGCGTCTGTTTGGATTGACGCGGCCACCCAGGTGTGCTTC
TCCCTGGGCGTGGGGTTCGGGGTGCTGATCGCCTTCTCCAGCTACAACAAGTTCACCAAC
AACTGCTACAGGGACGCGATTGTCACCACCTCCATCAACTCCCTGACGAGCTTCTCCTCC
GGCTTCGTCGTCTTCTCCTTCCTGGGGTACATGGCACAGAAGCACAGTGTGCCCATCGGG
GACGTGGCCAAGGACGGGCCAGGGCTGATCTTCATCATCTACCCGGAAGCCATCGCCACG
CTCCCTCTGTCCTCAGCCTGGGCCGTGGTCTTCTTCATCATGCTGCTCACCCTGGGTATC
GACAGCGCCATGGGTGGTATGGAGTCAGTGATCACCGGGCTCATCGATGAGTTCCAGCTG
CTGCACAGACACCGTGAGCTCTTCACGCTCTTCATCGTCCTGGCGACCTTCCTCCTGTCC
CTGTTCTGCGTCACCAACGGTGGCATCTACGTCTTCACGCTCCTGGACCATTTTGCAGCC
GGCACGTCCATCCTCTTTGGAGTGCTCATCGAAGCCATCGGAGTGGCCTGGTTCTATGGT
GTTGGGCAGTTCAGCGACGACATCCAGCAGATGACCGGGCAGCGGCCCAGCCTGTACTGG
CGGCTGTGCTGGAAGCTGGTCAGCCCCTGCTTTCTCCTGTTCGTGGTCGTGGTCAGCATT
GTGACCTTCAGACCCCCCCACTACGGAGCCTACATCTTCCCCGACTGGGCCAACGCGCTG
GGCTGGGTCATCGCCACATCCTCCATGGCCATGGTGCCCATCTATGCGGCCTACAAGTTC
TGCAGCCTGCCTGGGTCCTTTCGAGAGAAACTGGCCTACGCCATTGCACCCGAGAAGGAC
CGTGAGCTGGTGGACAGAGGGGAGGTGCGCCAGTTCACGCTCCGCCACTGGCTCAAGGTG
TAG</gene_sequence>
  </gene_properties>
  <protein_properties>
    <residue_number>620</residue_number>
    <molecular_weight>68494.255</molecular_weight>
    <theoretical_pi>6.919</theoretical_pi>
    <pfams>
      <pfam>
        <name>SNF</name>
        <pfam_id>PF00209</pfam_id>
      </pfam>
    </pfams>
    <transmembrane_regions>
    </transmembrane_regions>
    <signal_regions>
    </signal_regions>
    <protein_sequence>&gt;Sodium-dependent dopamine transporter
MSKSKCSVGLMSSVVAPAKEPNAVGPKEVELILVKEQNGVQLTSSTLTNPRQSPVEAQDR
ETWGKKIDFLLSVIGFAVDLANVWRFPYLCYKNGGGAFLVPYLLFMVIAGMPLFYMELAL
GQFNREGAAGVWKICPILKGVGFTVILISLYVGFFYNVIIAWALHYLFSSFTTELPWIHC
NNSWNSPNCSDAHPGDSSGDSSGLNDTFGTTPAAEYFERGVLHLHQSHGIDDLGPPRWQL
TACLVLVIVLLYFSLWKGVKTSGKVVWITATMPYVVLTALLLRGVTLPGAIDGIRAYLSV
DFYRLCEASVWIDAATQVCFSLGVGFGVLIAFSSYNKFTNNCYRDAIVTTSINSLTSFSS
GFVVFSFLGYMAQKHSVPIGDVAKDGPGLIFIIYPEAIATLPLSSAWAVVFFIMLLTLGI
DSAMGGMESVITGLIDEFQLLHRHRELFTLFIVLATFLLSLFCVTNGGIYVFTLLDHFAA
GTSILFGVLIEAIGVAWFYGVGQFSDDIQQMTGQRPSLYWRLCWKLVSPCFLLFVVVVSI
VTFRPPHYGAYIFPDWANALGWVIATSSMAMVPIYAAYKFCSLPGSFREKLAYAIAPEKD
RELVDRGEVRQFTLRHWLKV</protein_sequence>
  </protein_properties>
  <genbank_protein_id>181656</genbank_protein_id>
  <uniprot_id>Q01959</uniprot_id>
  <uniprot_name>SC6A3_HUMAN</uniprot_name>
  <pdb_ids>
  </pdb_ids>
  <genbank_gene_id>M95167</genbank_gene_id>
  <genecard_id>SLC6A3</genecard_id>
  <geneatlas_id>SLC6A3</geneatlas_id>
  <hgnc_id>HGNC:11049</hgnc_id>
  <general_references>
    <reference>
      <reference_text>Vandenbergh DJ, Persico AM, Uhl GR: A human dopamine transporter cDNA predicts reduced glycosylation, displays a novel repetitive element and provides racially-dimorphic TaqI RFLPs. Brain Res Mol Brain Res. 1992 Sep;15(1-2):161-6.</reference_text>
      <pubmed_id>1359373</pubmed_id>
    </reference>
    <reference>
      <reference_text>Giros B, el Mestikawy S, Godinot N, Zheng K, Han H, Yang-Feng T, Caron MG: Cloning, pharmacological characterization, and chromosome assignment of the human dopamine transporter. Mol Pharmacol. 1992 Sep;42(3):383-90.</reference_text>
      <pubmed_id>1406597</pubmed_id>
    </reference>
    <reference>
      <reference_text>Pristupa ZB, Wilson JM, Hoffman BJ, Kish SJ, Niznik HB: Pharmacological heterogeneity of the cloned and native human dopamine transporter: disassociation of [3H]WIN 35,428 and [3H]GBR 12,935 binding. Mol Pharmacol. 1994 Jan;45(1):125-35.</reference_text>
      <pubmed_id>8302271</pubmed_id>
    </reference>
    <reference>
      <reference_text>Kawarai T, Kawakami H, Yamamura Y, Nakamura S: Structure and organization of the gene encoding human dopamine transporter. Gene. 1997 Aug 11;195(1):11-8.</reference_text>
      <pubmed_id>9300814</pubmed_id>
    </reference>
    <reference>
      <reference_text>Vandenbergh DJ, Thompson MD, Cook EH, Bendahhou E, Nguyen T, Krasowski MD, Zarrabian D, Comings D, Sellers EM, Tyndale RF, George SR, O'Dowd BF, Uhl GR: Human dopamine transporter gene: coding region conservation among normal, Tourette's disorder, alcohol dependence and attention-deficit hyperactivity disorder populations. Mol Psychiatry. 2000 May;5(3):283-92.</reference_text>
      <pubmed_id>10889531</pubmed_id>
    </reference>
    <reference>
      <reference_text>Greenwood TA, Alexander M, Keck PE, McElroy S, Sadovnick AD, Remick RA, Kelsoe JR: Evidence for linkage disequilibrium between the dopamine transporter and bipolar disorder. Am J Med Genet. 2001 Mar 8;105(2):145-51.</reference_text>
      <pubmed_id>11304827</pubmed_id>
    </reference>
    <reference>
      <reference_text>Donovan DM, Vandenbergh DJ, Perry MP, Bird GS, Ingersoll R, Nanthakumar E, Uhl GR: Human and mouse dopamine transporter genes: conservation of 5'-flanking sequence elements and gene structures. Brain Res Mol Brain Res. 1995 Jun;30(2):327-35.</reference_text>
      <pubmed_id>7637582</pubmed_id>
    </reference>
    <reference>
      <reference_text>Bannon MJ, Poosch MS, Xia Y, Goebel DJ, Cassin B, Kapatos G: Dopamine transporter mRNA content in human substantia nigra decreases precipitously with age. Proc Natl Acad Sci U S A. 1992 Aug 1;89(15):7095-9.</reference_text>
      <pubmed_id>1353885</pubmed_id>
    </reference>
    <reference>
      <reference_text>Torres GE, Yao WD, Mohn AR, Quan H, Kim KM, Levey AI, Staudinger J, Caron MG: Functional interaction between monoamine plasma membrane transporters and the synaptic PDZ domain-containing protein PICK1. Neuron. 2001 Apr;30(1):121-34.</reference_text>
      <pubmed_id>11343649</pubmed_id>
    </reference>
    <reference>
      <reference_text>Carneiro AM, Ingram SL, Beaulieu JM, Sweeney A, Amara SG, Thomas SM, Caron MG, Torres GE: The multiple LIM domain-containing adaptor protein Hic-5 synaptically colocalizes and interacts with the dopamine transporter. J Neurosci. 2002 Aug 15;22(16):7045-54.</reference_text>
      <pubmed_id>12177201</pubmed_id>
    </reference>
    <reference>
      <reference_text>Cargill M, Altshuler D, Ireland J, Sklar P, Ardlie K, Patil N, Shaw N, Lane CR, Lim EP, Kalyanaraman N, Nemesh J, Ziaugra L, Friedland L, Rolfe A, Warrington J, Lipshutz R, Daley GQ, Lander ES: Characterization of single-nucleotide polymorphisms in coding regions of human genes. Nat Genet. 1999 Jul;22(3):231-8.</reference_text>
      <pubmed_id>10391209</pubmed_id>
    </reference>
    <reference>
      <reference_text>Sjoblom T, Jones S, Wood LD, Parsons DW, Lin J, Barber TD, Mandelker D, Leary RJ, Ptak J, Silliman N, Szabo S, Buckhaults P, Farrell C, Meeh P, Markowitz SD, Willis J, Dawson D, Willson JK, Gazdar AF, Hartigan J, Wu L, Liu C, Parmigiani G, Park BH, Bachman KE, Papadopoulos N, Vogelstein B, Kinzler KW, Velculescu VE: The consensus coding sequences of human breast and colorectal cancers.  Science. 2006 Oct 13;314(5797):268-74. Epub 2006 Sep 7.</reference_text>
      <pubmed_id>16959974</pubmed_id>
    </reference>
  </general_references>
  <metabolite_references>
    <metabolite_reference>
      <metabolite>
        <name>Dopamine</name>
        <accession>HMDB00073</accession>
      </metabolite>
      <reference>
        <reference_text>Ostadali MR, Ahangari G, Eslami MB, Razavi A, Zarrindast MR, Ahmadkhaniha HR, Boulhari J: The Detection of Dopamine Gene Receptors (DRD1-DRD5) Expression on Human Peripheral Blood Lymphocytes by Real Time PCR. Iran J Allergy Asthma Immunol. 2004 Dec;3(4):169-74.</reference_text>
        <pubmed_id>17301410</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Amphetamine</name>
        <accession>HMDB14328</accession>
      </metabolite>
      <reference>
        <reference_text>Lott DC, Kim SJ, Cook EH Jr, de Wit H: Dopamine transporter gene associated with diminished subjective response to amphetamine. Neuropsychopharmacology. 2005 Mar;30(3):602-9.</reference_text>
        <pubmed_id>15602501</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Amphetamine</name>
        <accession>HMDB14328</accession>
      </metabolite>
      <reference>
        <reference_text>Fone KC, Nutt DJ: Stimulants: use and abuse in the treatment of attention deficit hyperactivity disorder. Curr Opin Pharmacol. 2005 Feb;5(1):87-93.</reference_text>
        <pubmed_id>15661631</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Amphetamine</name>
        <accession>HMDB14328</accession>
      </metabolite>
      <reference>
        <reference_text>Miller GM, Verrico CD, Jassen A, Konar M, Yang H, Panas H, Bahn M, Johnson R, Madras BK: Primate trace amine receptor 1 modulation by the dopamine transporter.  J Pharmacol Exp Ther. 2005 Jun;313(3):983-94. Epub 2005 Mar 11.</reference_text>
        <pubmed_id>15764732</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Amphetamine</name>
        <accession>HMDB14328</accession>
      </metabolite>
      <reference>
        <reference_text>Garcia BG, Wei Y, Moron JA, Lin RZ, Javitch JA, Galli A: Akt is essential for insulin modulation of amphetamine-induced human dopamine transporter cell-surface redistribution. Mol Pharmacol. 2005 Jul;68(1):102-9. Epub 2005 Mar 28.</reference_text>
        <pubmed_id>15795321</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Amphetamine</name>
        <accession>HMDB14328</accession>
      </metabolite>
      <reference>
        <reference_text>Madras BK, Miller GM, Fischman AJ: The dopamine transporter and attention-deficit/hyperactivity disorder.  Biol Psychiatry. 2005 Jun 1;57(11):1397-409. Epub 2005 Jan 5.</reference_text>
        <pubmed_id>15950014</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Amphetamine</name>
        <accession>HMDB14328</accession>
      </metabolite>
      <reference>
        <reference_text>Kahlig KM, Binda F, Khoshbouei H, Blakely RD, McMahon DG, Javitch JA, Galli A: Amphetamine induces dopamine efflux through a dopamine transporter channel.  Proc Natl Acad Sci U S A. 2005 Mar 1;102(9):3495-500. Epub 2005 Feb 22.</reference_text>
        <pubmed_id>15728379</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Phentermine</name>
        <accession>HMDB14337</accession>
      </metabolite>
      <reference>
        <reference_text>John CE, Jones SR: Voltammetric characterization of the effect of monoamine uptake inhibitors and releasers on dopamine and serotonin uptake in mouse caudate-putamen and substantia nigra slices. Neuropharmacology. 2007 Jun;52(8):1596-605. Epub 2007 Mar 16.</reference_text>
        <pubmed_id>17459426</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Phentermine</name>
        <accession>HMDB14337</accession>
      </metabolite>
      <reference>
        <reference_text>Gruner JA, Marcy VR, Lin YG, Bozyczko-Coyne D, Marino MJ, Gasior M: The roles of dopamine transport inhibition and dopamine release facilitation in wake enhancement and rebound hypersomnolence induced by dopaminergic agents. Sleep. 2009 Nov;32(11):1425-38.</reference_text>
        <pubmed_id>19928382</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Benzatropine</name>
        <accession>HMDB14390</accession>
      </metabolite>
      <reference>
        <reference_text>Katz JL, Agoston GE, Alling KL, Kline RH, Forster MJ, Woolverton WL, Kopajtic TA, Newman AH: Dopamine transporter binding without cocaine-like behavioral effects: synthesis and evaluation of benztropine analogs alone and in combination with cocaine in rodents. Psychopharmacology (Berl). 2001 Apr;154(4):362-74.</reference_text>
        <pubmed_id>11349389</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Benzatropine</name>
        <accession>HMDB14390</accession>
      </metabolite>
      <reference>
        <reference_text>Kulkarni SS, Kopajtic TA, Katz JL, Newman AH: Comparative structure-activity relationships of benztropine analogues at the dopamine transporter and histamine H(1) receptors. Bioorg Med Chem. 2006 Jun 1;14(11):3625-34. Epub 2006 Feb 3.</reference_text>
        <pubmed_id>16460947</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Benzatropine</name>
        <accession>HMDB14390</accession>
      </metabolite>
      <reference>
        <reference_text>Reith ME, Berfield JL, Wang LC, Ferrer JV, Javitch JA: The uptake inhibitors cocaine and benztropine differentially alter the conformation of the human dopamine transporter. J Biol Chem. 2001 Aug 3;276(31):29012-8. Epub 2001 Jun 6.</reference_text>
        <pubmed_id>11395483</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Benzatropine</name>
        <accession>HMDB14390</accession>
      </metabolite>
      <reference>
        <reference_text>Simoni D, Roberti M, Rondanin R, Baruchello R, Rossi M, Invidiata FP, Merighi S, Varani K, Gessi S, Borea PA, Marino S, Cavallini S, Bianchi C, Siniscalchi A: Effects of two-carbon bridge region methoxylation of benztropine: discovery of novel chiral ligands for the dopamine transporter. Bioorg Med Chem Lett. 2001 Mar 26;11(6):823-7.</reference_text>
        <pubmed_id>11277529</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Benzatropine</name>
        <accession>HMDB14390</accession>
      </metabolite>
      <reference>
        <reference_text>Todd CL, Grace AA: Interaction of benztropine and haloperidol actions on rat substantia nigra dopamine cell electrophysiological activity in vivo. Brain Res Bull. 1999 Jan 15;48(2):219-22.</reference_text>
        <pubmed_id>10230713</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Benzatropine</name>
        <accession>HMDB14390</accession>
      </metabolite>
      <reference>
        <reference_text>Zou MF, Kopajtic T, Katz JL, Wirtz S, Justice JB Jr, Newman AH: Novel tropane-based irreversible ligands for the dopamine transporter.  J Med Chem. 2001 Dec 6;44(25):4453-61.</reference_text>
        <pubmed_id>11728190</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Methylphenidate</name>
        <accession>HMDB14566</accession>
      </metabolite>
      <reference>
        <reference_text>Volkow ND, Fowler JS, Gatley SJ, Dewey SL, Wang GJ, Logan J, Ding YS, Franceschi D, Gifford A, Morgan A, Pappas N, King P: Comparable changes in synaptic dopamine induced by methylphenidate and by cocaine in the baboon brain. Synapse. 1999 Jan;31(1):59-66.</reference_text>
        <pubmed_id>10025684</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Methylphenidate</name>
        <accession>HMDB14566</accession>
      </metabolite>
      <reference>
        <reference_text>Wayment HK, Deutsch H, Schweri MM, Schenk JO: Effects of methylphenidate analogues on phenethylamine substrates for the striatal dopamine transporter: potential as amphetamine antagonists? J Neurochem. 1999 Mar;72(3):1266-74.</reference_text>
        <pubmed_id>10037500</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Methylphenidate</name>
        <accession>HMDB14566</accession>
      </metabolite>
      <reference>
        <reference_text>Dresel SH, Kung MP, Huang X, Plossl K, Hou C, Shiue CY, Karp J, Kung HF: In vivo imaging of serotonin transporters with [99mTc]TRODAT-1 in nonhuman primates. Eur J Nucl Med. 1999 Apr;26(4):342-7.</reference_text>
        <pubmed_id>10199939</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Methylphenidate</name>
        <accession>HMDB14566</accession>
      </metabolite>
      <reference>
        <reference_text>Volkow ND, Wang GJ, Fowler JS, Fischman M, Foltin R, Abumrad NN, Gatley SJ, Logan J, Wong C, Gifford A, Ding YS, Hitzemann R, Pappas N: Methylphenidate and cocaine have a similar in vivo potency to block dopamine transporters in the human brain. Life Sci. 1999;65(1):PL7-12.</reference_text>
        <pubmed_id>10403500</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Methylphenidate</name>
        <accession>HMDB14566</accession>
      </metabolite>
      <reference>
        <reference_text>Izenwasser S, Coy AE, Ladenheim B, Loeloff RJ, Cadet JL, French D: Chronic methylphenidate alters locomotor activity and dopamine transporters differently from cocaine. Eur J Pharmacol. 1999 Jun 4;373(2-3):187-93.</reference_text>
        <pubmed_id>10414438</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Methylphenidate</name>
        <accession>HMDB14566</accession>
      </metabolite>
      <reference>
        <reference_text>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database.  Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</reference_text>
        <pubmed_id>11752352</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Methylphenidate</name>
        <accession>HMDB14566</accession>
      </metabolite>
      <reference>
        <reference_text>Tatsumi M, Groshan K, Blakely RD, Richelson E: Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol. 1997 Dec 11;340(2-3):249-58.</reference_text>
        <pubmed_id>9537821</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Methylphenidate</name>
        <accession>HMDB14566</accession>
      </metabolite>
      <reference>
        <reference_text>Viggiano D, Vallone D, Sadile A: Dysfunctions in dopamine systems and ADHD: evidence from animals and modeling.  Neural Plast. 2004;11(1-2):97-114.</reference_text>
        <pubmed_id>15303308</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Methylphenidate</name>
        <accession>HMDB14566</accession>
      </metabolite>
      <reference>
        <reference_text>Tilley MR, Gu HH: The effects of methylphenidate on knockin mice with a methylphenidate-resistant dopamine transporter. J Pharmacol Exp Ther. 2008 Nov;327(2):554-60. Epub 2008 Aug 12.</reference_text>
        <pubmed_id>18698001</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Duloxetine</name>
        <accession>HMDB14619</accession>
      </metabolite>
      <reference>
        <reference_text>Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there?  Nat Rev Drug Discov. 2006 Dec;5(12):993-6.</reference_text>
        <pubmed_id>17139284</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Duloxetine</name>
        <accession>HMDB14619</accession>
      </metabolite>
      <reference>
        <reference_text>Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets.  Nat Rev Drug Discov. 2006 Oct;5(10):821-34.</reference_text>
        <pubmed_id>17016423</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Duloxetine</name>
        <accession>HMDB14619</accession>
      </metabolite>
      <reference>
        <reference_text>Carter NJ, McCormack PL: Duloxetine: a review of its use in the treatment of generalized anxiety disorder.  CNS Drugs. 2009;23(6):523-41. doi: 10.2165/00023210-200923060-00006.</reference_text>
        <pubmed_id>19480470</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Duloxetine</name>
        <accession>HMDB14619</accession>
      </metabolite>
      <reference>
        <reference_text>Pereira P, Gianesini J, da Silva Barbosa C, Cassol GF, Von Borowski RG, Kahl VF, Cappelari SE, Picada JN: Neurobehavioral and genotoxic parameters of duloxetine in mice using the inhibitory avoidance task and comet assay as experimental models. Pharmacol Res. 2009 Jan;59(1):57-61. Epub 2008 Oct 5.</reference_text>
        <pubmed_id>18973814</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Duloxetine</name>
        <accession>HMDB14619</accession>
      </metabolite>
      <reference>
        <reference_text>Hunziker ME, Suehs BT, Bettinger TL, Crismon ML: Duloxetine hydrochloride: a new dual-acting medication for the treatment of major depressive disorder. Clin Ther. 2005 Aug;27(8):1126-43.</reference_text>
        <pubmed_id>16199241</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Mazindol</name>
        <accession>HMDB14718</accession>
      </metabolite>
      <reference>
        <reference_text>Itzhak Y, Martin JL: Effects of cocaine, nicotine, dizocipline and alcohol on mice locomotor activity: cocaine-alcohol cross-sensitization involves upregulation of striatal dopamine transporter binding sites. Brain Res. 1999 Feb 13;818(2):204-11.</reference_text>
        <pubmed_id>10082805</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Mazindol</name>
        <accession>HMDB14718</accession>
      </metabolite>
      <reference>
        <reference_text>Saunders C, Ferrer JV, Shi L, Chen J, Merrill G, Lamb ME, Leeb-Lundberg LM, Carvelli L, Javitch JA, Galli A: Amphetamine-induced loss of human dopamine transporter activity: an internalization-dependent and cocaine-sensitive mechanism. Proc Natl Acad Sci U S A. 2000 Jun 6;97(12):6850-5.</reference_text>
        <pubmed_id>10823899</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Mazindol</name>
        <accession>HMDB14718</accession>
      </metabolite>
      <reference>
        <reference_text>Goettl VM, Wemlinger TA, Fong TG, Neff NH, Hadjiconstantinou M: Retinal cholinergic and dopaminergic deficits of aged rats are improved following treatment with GM1 ganglioside. Brain Res. 2000 Sep 15;877(1):1-6.</reference_text>
        <pubmed_id>10980236</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Mazindol</name>
        <accession>HMDB14718</accession>
      </metabolite>
      <reference>
        <reference_text>Tidjane Corera A, Do-Rego JC, Costentin J, Bonnet JJ: Differential sensitivity to NaCl for inhibitors and substrates that recognize mutually exclusive binding sites on the neuronal transporter of dopamine in rat striatal membranes. Neurosci Res. 2001 Mar;39(3):319-25.</reference_text>
        <pubmed_id>11248372</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Mazindol</name>
        <accession>HMDB14718</accession>
      </metabolite>
      <reference>
        <reference_text>Purkerson-Parker S, McDaniel KL, Moser VC: Dopamine transporter binding in the rat striatum is increased by gestational, perinatal, and adolescent exposure to heptachlor. Toxicol Sci. 2001 Dec;64(2):216-23.</reference_text>
        <pubmed_id>11719704</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Mazindol</name>
        <accession>HMDB14718</accession>
      </metabolite>
      <reference>
        <reference_text>Tatsumi M, Groshan K, Blakely RD, Richelson E: Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol. 1997 Dec 11;340(2-3):249-58.</reference_text>
        <pubmed_id>9537821</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Mazindol</name>
        <accession>HMDB14718</accession>
      </metabolite>
      <reference>
        <reference_text>Kulkarni SS, Newman AH, Houlihan WJ: Three-dimensional quantitative structure-activity relationships of mazindol analogues at the dopamine transporter. J Med Chem. 2002 Sep 12;45(19):4119-27.</reference_text>
        <pubmed_id>12213055</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Mazindol</name>
        <accession>HMDB14718</accession>
      </metabolite>
      <reference>
        <reference_text>Houlihan WJ, Kelly L, Pankuch J, Koletar J, Brand L, Janowsky A, Kopajtic TA: Mazindol analogues as potential inhibitors of the cocaine binding site at the dopamine transporter. J Med Chem. 2002 Sep 12;45(19):4097-109.</reference_text>
        <pubmed_id>12213053</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Procaine</name>
        <accession>HMDB14859</accession>
      </metabolite>
      <reference>
        <reference_text>Sato T, Kitayama S, Mitsuhata C, Ikeda T, Morita K, Dohi T: Selective inhibition of monoamine neurotransmitter transporters by synthetic local anesthetics. Naunyn Schmiedebergs Arch Pharmacol. 2000 Feb;361(2):214-20.</reference_text>
        <pubmed_id>10685879</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Procaine</name>
        <accession>HMDB14859</accession>
      </metabolite>
      <reference>
        <reference_text>Wilcox KM, Kimmel HL, Lindsey KP, Votaw JR, Goodman MM, Howell LL: In vivo comparison of the reinforcing and dopamine transporter effects of local anesthetics in rhesus monkeys. Synapse. 2005 Dec 15;58(4):220-8.</reference_text>
        <pubmed_id>16206183</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Procaine</name>
        <accession>HMDB14859</accession>
      </metabolite>
      <reference>
        <reference_text>Kiyatkin EA, Brown PL: The role of peripheral and central sodium channels in mediating brain temperature fluctuations induced by intravenous cocaine. Brain Res. 2006 Oct 30;1117(1):38-53. Epub 2006 Sep 7.</reference_text>
        <pubmed_id>16956595</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Trimipramine</name>
        <accession>HMDB14864</accession>
      </metabolite>
      <reference>
        <reference_text>Tatsumi M, Groshan K, Blakely RD, Richelson E: Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol. 1997 Dec 11;340(2-3):249-58.</reference_text>
        <pubmed_id>9537821</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Modafinil</name>
        <accession>HMDB14883</accession>
      </metabolite>
      <reference>
        <reference_text>Zhou J, He R, Johnson KM, Ye Y, Kozikowski AP: Piperidine-based nocaine/modafinil hybrid ligands as highly potent monoamine transporter inhibitors: efficient drug discovery by rational lead hybridization. J Med Chem. 2004 Nov 18;47(24):5821-4.</reference_text>
        <pubmed_id>15537337</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Modafinil</name>
        <accession>HMDB14883</accession>
      </metabolite>
      <reference>
        <reference_text>Madras BK, Xie Z, Lin Z, Jassen A, Panas H, Lynch L, Johnson R, Livni E, Spencer TJ, Bonab AA, Miller GM, Fischman AJ: Modafinil occupies dopamine and norepinephrine transporters in vivo and modulates the transporters and trace amine activity in vitro. J Pharmacol Exp Ther. 2006 Nov;319(2):561-9. Epub 2006 Aug 2.</reference_text>
        <pubmed_id>16885432</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Modafinil</name>
        <accession>HMDB14883</accession>
      </metabolite>
      <reference>
        <reference_text>Swanson JM: Role of executive function in ADHD.  J Clin Psychiatry. 2003;64 Suppl 14:35-9.</reference_text>
        <pubmed_id>14658934</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Modafinil</name>
        <accession>HMDB14883</accession>
      </metabolite>
      <reference>
        <reference_text>Dopheide MM, Morgan RE, Rodvelt KR, Schachtman TR, Miller DK: Modafinil evokes striatal [(3)H]dopamine release and alters the subjective properties of stimulants. Eur J Pharmacol. 2007 Jul 30;568(1-3):112-23. Epub 2007 Apr 5.</reference_text>
        <pubmed_id>17477916</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Modafinil</name>
        <accession>HMDB14883</accession>
      </metabolite>
      <reference>
        <reference_text>Wisor JP, Nishino S, Sora I, Uhl GH, Mignot E, Edgar DM: Dopaminergic role in stimulant-induced wakefulness.  J Neurosci. 2001 Mar 1;21(5):1787-94.</reference_text>
        <pubmed_id>11222668</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Phenmetrazine</name>
        <accession>HMDB14968</accession>
      </metabolite>
      <reference>
        <reference_text>Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there?  Nat Rev Drug Discov. 2006 Dec;5(12):993-6.</reference_text>
        <pubmed_id>17139284</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Phenmetrazine</name>
        <accession>HMDB14968</accession>
      </metabolite>
      <reference>
        <reference_text>Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets.  Nat Rev Drug Discov. 2006 Oct;5(10):821-34.</reference_text>
        <pubmed_id>17016423</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Phenmetrazine</name>
        <accession>HMDB14968</accession>
      </metabolite>
      <reference>
        <reference_text>Rothman RB, Katsnelson M, Vu N, Partilla JS, Dersch CM, Blough BE, Baumann MH: Interaction of the anorectic medication, phendimetrazine, and its metabolites with monoamine transporters in rat brain. Eur J Pharmacol. 2002 Jun 28;447(1):51-7.</reference_text>
        <pubmed_id>12106802</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Phenmetrazine</name>
        <accession>HMDB14968</accession>
      </metabolite>
      <reference>
        <reference_text>Rothman RB, Baumann MH: Therapeutic potential of monoamine transporter substrates.  Curr Top Med Chem. 2006;6(17):1845-59.</reference_text>
        <pubmed_id>17017961</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Benzphetamine</name>
        <accession>HMDB15003</accession>
      </metabolite>
      <reference>
        <reference_text>Sulzer D, Sonders MS, Poulsen NW, Galli A: Mechanisms of neurotransmitter release by amphetamines: a review.  Prog Neurobiol. 2005 Apr;75(6):406-33.</reference_text>
        <pubmed_id>15955613</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Benzphetamine</name>
        <accession>HMDB15003</accession>
      </metabolite>
      <reference>
        <reference_text>Kahlig KM, Binda F, Khoshbouei H, Blakely RD, McMahon DG, Javitch JA, Galli A: Amphetamine induces dopamine efflux through a dopamine transporter channel.  Proc Natl Acad Sci U S A. 2005 Mar 1;102(9):3495-500. Epub 2005 Feb 22.</reference_text>
        <pubmed_id>15728379</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Cocaine</name>
        <accession>HMDB15043</accession>
      </metabolite>
      <reference>
        <reference_text>Wilson JM, Levey AI, Bergeron C, Kalasinsky K, Ang L, Peretti F, Adams VI, Smialek J, Anderson WR, Shannak K, Deck J, Niznik HB, Kish SJ: Striatal dopamine, dopamine transporter, and vesicular monoamine transporter in chronic cocaine users. Ann Neurol. 1996 Sep;40(3):428-39.</reference_text>
        <pubmed_id>8797532</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Cocaine</name>
        <accession>HMDB15043</accession>
      </metabolite>
      <reference>
        <reference_text>Kim DI, Schweri MM, Deutsch HM: Synthesis and pharmacology of site specific cocaine abuse treatment agents: 8-substituted isotropane (3-azabicyclo[3.2.1]octane) dopamine uptake inhibitors. J Med Chem. 2003 Apr 10;46(8):1456-64.</reference_text>
        <pubmed_id>12672245</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Cocaine</name>
        <accession>HMDB15043</accession>
      </metabolite>
      <reference>
        <reference_text>Rothman RB, Baumann MH, Dersch CM, Appel J, Houghten RA: Discovery of novel peptidic dopamine transporter ligands by screening a positional scanning combinatorial hexapeptide library. Synapse. 1999 Sep 1;33(3):239-46.</reference_text>
        <pubmed_id>10420171</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Cocaine</name>
        <accession>HMDB15043</accession>
      </metabolite>
      <reference>
        <reference_text>Carrera MR, Meijler MM, Janda KD: Cocaine pharmacology and current pharmacotherapies for its abuse.  Bioorg Med Chem. 2004 Oct 1;12(19):5019-30.</reference_text>
        <pubmed_id>15351386</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Cocaine</name>
        <accession>HMDB15043</accession>
      </metabolite>
      <reference>
        <reference_text>Tatsumi M, Groshan K, Blakely RD, Richelson E: Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol. 1997 Dec 11;340(2-3):249-58.</reference_text>
        <pubmed_id>9537821</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Diethylpropion</name>
        <accession>HMDB15072</accession>
      </metabolite>
      <reference>
        <reference_text>Yu H, Rothman RB, Dersch CM, Partilla JS, Rice KC: Uptake and release effects of diethylpropion and its metabolites with biogenic amine transporters. Bioorg Med Chem. 2000 Dec;8(12):2689-92.</reference_text>
        <pubmed_id>11131159</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Diethylpropion</name>
        <accession>HMDB15072</accession>
      </metabolite>
      <reference>
        <reference_text>Arias HR, Santamaria A, Ali SF: Pharmacological and neurotoxicological actions mediated by bupropion and diethylpropion. Int Rev Neurobiol. 2009;88:223-55.</reference_text>
        <pubmed_id>19897080</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Sibutramine</name>
        <accession>HMDB15237</accession>
      </metabolite>
      <reference>
        <reference_text>Tziomalos K, Krassas GE, Tzotzas T: The use of sibutramine in the management of obesity and related disorders: an update. Vasc Health Risk Manag. 2009;5(1):441-52.</reference_text>
        <pubmed_id>19475780</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Sibutramine</name>
        <accession>HMDB15237</accession>
      </metabolite>
      <reference>
        <reference_text>Gomis Barbara R: [Pharmacological treatment of obesity].  Rev Med Univ Navarra. 2004 Apr-Jun;48(2):63-5.</reference_text>
        <pubmed_id>15382615</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Sibutramine</name>
        <accession>HMDB15237</accession>
      </metabolite>
      <reference>
        <reference_text>Berke EM, Morden NE: Medical management of obesity.  Am Fam Physician. 2000 Jul 15;62(2):419-26.</reference_text>
        <pubmed_id>10929704</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Sibutramine</name>
        <accession>HMDB15237</accession>
      </metabolite>
      <reference>
        <reference_text>Nakagawa T, Ukai K, Ohyama T, Gomita Y, Okamura H: Effects of sibutramine on the central dopaminergic system in rodents.  Neurotox Res. 2001 Jul;3(3):235-47.</reference_text>
        <pubmed_id>15111248</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Sibutramine</name>
        <accession>HMDB15237</accession>
      </metabolite>
      <reference>
        <reference_text>Krahn LE, Moore WR, Altchuler SI: Narcolepsy and obesity: remission of severe cataplexy with sibutramine.  Sleep Med. 2001 Jan;2(1):63-65.</reference_text>
        <pubmed_id>11152984</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Sibutramine</name>
        <accession>HMDB15237</accession>
      </metabolite>
      <reference>
        <reference_text>Balcioglu A, Wurtman RJ: Sibutramine, a serotonin uptake inhibitor, increases dopamine concentrations in rat striatal and hypothalamic extracellular fluid. Neuropharmacology. 2000 Sep;39(12):2352-9.</reference_text>
        <pubmed_id>10974319</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Diphenylpyraline</name>
        <accession>HMDB15277</accession>
      </metabolite>
      <reference>
        <reference_text>Lapa GB, Mathews TA, Harp J, Budygin EA, Jones SR: Diphenylpyraline, a histamine H1 receptor antagonist, has psychostimulant properties. Eur J Pharmacol. 2005 Jan 4;506(3):237-40. Epub 2004 Dec 8.</reference_text>
        <pubmed_id>15627433</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Nefazodone</name>
        <accession>HMDB15280</accession>
      </metabolite>
      <reference>
        <reference_text>Tatsumi M, Groshan K, Blakely RD, Richelson E: Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol. 1997 Dec 11;340(2-3):249-58.</reference_text>
        <pubmed_id>9537821</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Chloroprocaine</name>
        <accession>HMDB15292</accession>
      </metabolite>
      <reference>
        <reference_text>Wilcox KM, Paul IA, Ordway GA, Woolverton WL: Role of the dopamine transporter and the sodium channel in the cocaine-like discriminative stimulus effects of local anesthetics in rats. Psychopharmacology (Berl). 2001 Sep;157(3):260-8.</reference_text>
        <pubmed_id>11605081</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Chloroprocaine</name>
        <accession>HMDB15292</accession>
      </metabolite>
      <reference>
        <reference_text>Mansbach RS, Jortani SA, Balster RL: Discriminative stimulus effects of esteratic local anesthetics in squirrel monkeys. Eur J Pharmacol. 1995 Feb 14;274(1-3):167-73.</reference_text>
        <pubmed_id>7768269</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Chloroprocaine</name>
        <accession>HMDB15292</accession>
      </metabolite>
      <reference>
        <reference_text>Wilcox KM, Paul IA, Woolverton WL: Comparison between dopamine transporter affinity and self-administration potency of local anesthetics in rhesus monkeys. Eur J Pharmacol. 1999 Feb 19;367(2-3):175-81.</reference_text>
        <pubmed_id>10078990</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Chloroprocaine</name>
        <accession>HMDB15292</accession>
      </metabolite>
      <reference>
        <reference_text>Wilcox KM, Rowlett JK, Paul IA, Ordway GA, Woolverton WL: On the relationship between the dopamine transporter and the reinforcing effects of local anesthetics in rhesus monkeys: practical and theoretical concerns. Psychopharmacology (Berl). 2000 Dec;153(1):139-47.</reference_text>
        <pubmed_id>11255924</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Lisdexamfetamine</name>
        <accession>HMDB15385</accession>
      </metabolite>
      <reference>
        <reference_text>Hamidovic A, Dlugos A, Palmer AA, de Wit H: Polymorphisms in dopamine transporter (SLC6A3) are associated with stimulant effects of D-amphetamine: an exploratory pharmacogenetic study using healthy volunteers. Behav Genet. 2010 Mar;40(2):255-61. Epub 2010 Jan 21.</reference_text>
        <pubmed_id>20091113</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Fencamfamine</name>
        <accession>HMDB15508</accession>
      </metabolite>
      <reference>
        <reference_text>Seyfried CA: Dopamine uptake inhibiting versus dopamine releasing properties of fencamfamine: an in vitro study. Biochem Pharmacol. 1983 Aug 1;32(15):2329-31.</reference_text>
        <pubmed_id>6136281</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Fencamfamine</name>
        <accession>HMDB15508</accession>
      </metabolite>
      <reference>
        <reference_text>Li SM, Campbell BL, Katz JL: Interactions of cocaine with dopamine uptake inhibitors or dopamine releasers in rats discriminating cocaine. J Pharmacol Exp Ther. 2006 Jun;317(3):1088-96. Epub 2006 Feb 14.</reference_text>
        <pubmed_id>16478825</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Dextroamphetamine</name>
        <accession>HMDB15516</accession>
      </metabolite>
      <reference>
        <reference_text>Zhen J, Chen N, Reith ME: Differences in interactions with the dopamine transporter as revealed by diminishment of Na(+) gradient and membrane potential: dopamine versus other substrates. Neuropharmacology. 2005 Nov;49(6):769-79. Epub 2005 Aug 24.</reference_text>
        <pubmed_id>16122767</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Dextroamphetamine</name>
        <accession>HMDB15516</accession>
      </metabolite>
      <reference>
        <reference_text>Kuczenski R, Segal DS, Cho AK, Melega W: Hippocampus norepinephrine, caudate dopamine and serotonin, and behavioral responses to the stereoisomers of amphetamine and methamphetamine. J Neurosci. 1995 Feb;15(2):1308-17.</reference_text>
        <pubmed_id>7869099</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Dextroamphetamine</name>
        <accession>HMDB15516</accession>
      </metabolite>
      <reference>
        <reference_text>Rothman RB, Dersch CM, Ananthan S, Partilla JS: Studies of the biogenic amine transporters. 13. Identification of "agonist" and "antagonist" allosteric modulators of amphetamine-induced dopamine release. J Pharmacol Exp Ther. 2009 May;329(2):718-28. Epub 2009 Feb 24.</reference_text>
        <pubmed_id>19244097</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Methamphetamine</name>
        <accession>HMDB15517</accession>
      </metabolite>
      <reference>
        <reference_text>Escubedo E, Camarasa J, Chipana C, Garcia-Rates S, Pubill D: Involvement of nicotinic receptors in methamphetamine- and MDMA-induced neurotoxicity: pharmacological implications. Int Rev Neurobiol. 2009;88:121-66.</reference_text>
        <pubmed_id>19897077</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Methamphetamine</name>
        <accession>HMDB15517</accession>
      </metabolite>
      <reference>
        <reference_text>Lott DC, Kim SJ, Cook EH Jr, de Wit H: Dopamine transporter gene associated with diminished subjective response to amphetamine. Neuropsychopharmacology. 2005 Mar;30(3):602-9.</reference_text>
        <pubmed_id>15602501</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Methamphetamine</name>
        <accession>HMDB15517</accession>
      </metabolite>
      <reference>
        <reference_text>Fone KC, Nutt DJ: Stimulants: use and abuse in the treatment of attention deficit hyperactivity disorder. Curr Opin Pharmacol. 2005 Feb;5(1):87-93.</reference_text>
        <pubmed_id>15661631</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Methamphetamine</name>
        <accession>HMDB15517</accession>
      </metabolite>
      <reference>
        <reference_text>Miller GM, Verrico CD, Jassen A, Konar M, Yang H, Panas H, Bahn M, Johnson R, Madras BK: Primate trace amine receptor 1 modulation by the dopamine transporter.  J Pharmacol Exp Ther. 2005 Jun;313(3):983-94. Epub 2005 Mar 11.</reference_text>
        <pubmed_id>15764732</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Methamphetamine</name>
        <accession>HMDB15517</accession>
      </metabolite>
      <reference>
        <reference_text>Garcia BG, Wei Y, Moron JA, Lin RZ, Javitch JA, Galli A: Akt is essential for insulin modulation of amphetamine-induced human dopamine transporter cell-surface redistribution. Mol Pharmacol. 2005 Jul;68(1):102-9. Epub 2005 Mar 28.</reference_text>
        <pubmed_id>15795321</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Methamphetamine</name>
        <accession>HMDB15517</accession>
      </metabolite>
      <reference>
        <reference_text>Madras BK, Miller GM, Fischman AJ: The dopamine transporter and attention-deficit/hyperactivity disorder.  Biol Psychiatry. 2005 Jun 1;57(11):1397-409. Epub 2005 Jan 5.</reference_text>
        <pubmed_id>15950014</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Methamphetamine</name>
        <accession>HMDB15517</accession>
      </metabolite>
      <reference>
        <reference_text>Kahlig KM, Binda F, Khoshbouei H, Blakely RD, McMahon DG, Javitch JA, Galli A: Amphetamine induces dopamine efflux through a dopamine transporter channel.  Proc Natl Acad Sci U S A. 2005 Mar 1;102(9):3495-500. Epub 2005 Feb 22.</reference_text>
        <pubmed_id>15728379</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Methamphetamine</name>
        <accession>HMDB15517</accession>
      </metabolite>
      <reference>
        <reference_text>Fleckenstein AE, Volz TJ, Riddle EL, Gibb JW, Hanson GR: New insights into the mechanism of action of amphetamines.  Annu Rev Pharmacol Toxicol. 2007;47:681-98.</reference_text>
        <pubmed_id>17209801</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Dexmethylphenidate</name>
        <accession>HMDB15647</accession>
      </metabolite>
      <reference>
        <reference_text>Markowitz JS, Patrick KS: Differential pharmacokinetics and pharmacodynamics of methylphenidate enantiomers: does chirality matter? J Clin Psychopharmacol. 2008 Jun;28(3 Suppl 2):S54-61.</reference_text>
        <pubmed_id>18480678</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Dexmethylphenidate</name>
        <accession>HMDB15647</accession>
      </metabolite>
      <reference>
        <reference_text>Ding YS, Fowler JS, Volkow ND, Dewey SL, Wang GJ, Logan J, Gatley SJ, Pappas N: Chiral drugs: comparison of the pharmacokinetics of [11C]d-threo and L-threo-methylphenidate in the human and baboon brain. Psychopharmacology (Berl). 1997 May;131(1):71-8.</reference_text>
        <pubmed_id>9181638</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Dexmethylphenidate</name>
        <accession>HMDB15647</accession>
      </metabolite>
      <reference>
        <reference_text>Davids E, Zhang K, Tarazi FI, Baldessarini RJ: Stereoselective effects of methylphenidate on motor hyperactivity in juvenile rats induced by neonatal 6-hydroxydopamine lesioning. Psychopharmacology (Berl). 2002 Feb;160(1):92-8. Epub 2001 Dec 18.</reference_text>
        <pubmed_id>11862378</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Dexmethylphenidate</name>
        <accession>HMDB15647</accession>
      </metabolite>
      <reference>
        <reference_text>Volkow ND, Fowler JS, Gatley SJ, Dewey SL, Wang GJ, Logan J, Ding YS, Franceschi D, Gifford A, Morgan A, Pappas N, King P: Comparable changes in synaptic dopamine induced by methylphenidate and by cocaine in the baboon brain. Synapse. 1999 Jan;31(1):59-66.</reference_text>
        <pubmed_id>10025684</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Dexmethylphenidate</name>
        <accession>HMDB15647</accession>
      </metabolite>
      <reference>
        <reference_text>Wayment HK, Deutsch H, Schweri MM, Schenk JO: Effects of methylphenidate analogues on phenethylamine substrates for the striatal dopamine transporter: potential as amphetamine antagonists? J Neurochem. 1999 Mar;72(3):1266-74.</reference_text>
        <pubmed_id>10037500</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Dexmethylphenidate</name>
        <accession>HMDB15647</accession>
      </metabolite>
      <reference>
        <reference_text>Dresel SH, Kung MP, Huang X, Plossl K, Hou C, Shiue CY, Karp J, Kung HF: In vivo imaging of serotonin transporters with [99mTc]TRODAT-1 in nonhuman primates. Eur J Nucl Med. 1999 Apr;26(4):342-7.</reference_text>
        <pubmed_id>10199939</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Dexmethylphenidate</name>
        <accession>HMDB15647</accession>
      </metabolite>
      <reference>
        <reference_text>Volkow ND, Wang GJ, Fowler JS, Fischman M, Foltin R, Abumrad NN, Gatley SJ, Logan J, Wong C, Gifford A, Ding YS, Hitzemann R, Pappas N: Methylphenidate and cocaine have a similar in vivo potency to block dopamine transporters in the human brain. Life Sci. 1999;65(1):PL7-12.</reference_text>
        <pubmed_id>10403500</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Dexmethylphenidate</name>
        <accession>HMDB15647</accession>
      </metabolite>
      <reference>
        <reference_text>Izenwasser S, Coy AE, Ladenheim B, Loeloff RJ, Cadet JL, French D: Chronic methylphenidate alters locomotor activity and dopamine transporters differently from cocaine. Eur J Pharmacol. 1999 Jun 4;373(2-3):187-93.</reference_text>
        <pubmed_id>10414438</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Dexmethylphenidate</name>
        <accession>HMDB15647</accession>
      </metabolite>
      <reference>
        <reference_text>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database.  Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</reference_text>
        <pubmed_id>11752352</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Dexmethylphenidate</name>
        <accession>HMDB15647</accession>
      </metabolite>
      <reference>
        <reference_text>Tatsumi M, Groshan K, Blakely RD, Richelson E: Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol. 1997 Dec 11;340(2-3):249-58.</reference_text>
        <pubmed_id>9537821</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Dexmethylphenidate</name>
        <accession>HMDB15647</accession>
      </metabolite>
      <reference>
        <reference_text>Viggiano D, Vallone D, Sadile A: Dysfunctions in dopamine systems and ADHD: evidence from animals and modeling.  Neural Plast. 2004;11(1-2):97-114.</reference_text>
        <pubmed_id>15303308</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Dexmethylphenidate</name>
        <accession>HMDB15647</accession>
      </metabolite>
      <reference>
        <reference_text>Tilley MR, Gu HH: The effects of methylphenidate on knockin mice with a methylphenidate-resistant dopamine transporter. J Pharmacol Exp Ther. 2008 Nov;327(2):554-60. Epub 2008 Aug 12.</reference_text>
        <pubmed_id>18698001</pubmed_id>
      </reference>
    </metabolite_reference>
  </metabolite_references>
</protein>
